Diabetic Foot Ulcers - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Foot Ulcers - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Diabetic Foot Ulcers - Pipeline Review, H1 2016', provides an overview of the Diabetic Foot Ulcers pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
- The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Diabetic Foot Ulcers Overview 12
Therapeutics Development 13
Pipeline Products for Diabetic Foot Ulcers - Overview 13
Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 14
Diabetic Foot Ulcers - Therapeutics under Development by Companies 15
Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes 17
Diabetic Foot Ulcers - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Diabetic Foot Ulcers - Products under Development by Companies 22
Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes 25
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 26
Adocia 26
Bayer AG 27
CardioVascular BioTherapeutics, Inc. 28
Celgene Corporation 29
CytoTools AG 30
Dipexium Pharmaceuticals LLC 31
EyeGene, Inc. 32
FirstString Research, Inc. 33
GlaxoSmithKline Plc 34
Human Stem Cells Institute 35
Innovaxis 36
Izun Pharmaceuticals Corporation 37
Karyopharm Therapeutics, Inc. 38
Lytix Biopharma AS 39
MediWound Ltd. 40
NovaLead Pharma Pvt. Ltd. 41
Oneness Biotech Co., Ltd. 42
Osiris Therapeutics, Inc. 43
Pherecydes Pharma SA 44
Plurogen Therapeutics, Inc. 45
Sanofi 46
Stratatech Corporation 47
TechnoPhage SA 48
TGV-Laboratories 49
Theravasc, Inc. 50
Tissue Therapies Limited 51
USV Limited 52
Vida Therapeutics Inc. 53
ViroMed Co., Ltd. 54
Diabetic Foot Ulcers - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
ALLO-ASC - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AP-102 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
APO-2 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
becaplermin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Biochaperone PDGF-BB - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
CL-05 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CODA-001 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CVBT-141B - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cyndacel-M - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
daprodustat - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Drug for Diabetic Foot Ulcer - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
EG-Decorin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
epidermal growth factor biosimilar - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
EscharEx - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
esmolol hydrochloride - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Granexin - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Heberprot-P - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
IMSP-001 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
IZN-6D4 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
LTX-109 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
MT-003 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Mul-1867 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Neovasculgen - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Nu-2 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Nu-3 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
ON-101 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
OTI-1501 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
PDA-002 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
pexiganan acetate - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
PluroGel N - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
PP-2351 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
selinexor - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
sodium nitrite SR - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
TP-102 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
V-10 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
VF-001 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Vivefoot - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
VM-202 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
VTI-1000 Series - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Diabetic Foot Ulcers - Recent Pipeline Updates 126
Diabetic Foot Ulcers - Dormant Projects 150
Diabetic Foot Ulcers - Discontinued Products 153
Diabetic Foot Ulcers - Product Development Milestones 154
Featured News & Press Releases 154
Mar 28, 2016: Dipexium Pharmaceuticals Announces Issuance of Locilex Patent in Japan 154
Feb 04, 2016: Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials 154
Feb 02, 2016: MediWound EscharEx Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds 154
Jan 05, 2016: Izun Pharmaceuticals to Present at Biotech Showcase 2016 156
Oct 13, 2015: Izun Pharmaceuticals Announces Positive Results from Phase 2 Randomized Trial in Diabetic Foot Ulcers 156
Oct 06, 2015: Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds 157
Oct 01, 2015: Dipexium Pharmaceuticals Reaches 50% Enrollment in Second Pivotal Phase 3 Clinical Trial 158
Sep 21, 2015: Dipexium Pharmaceuticals Presents Locilex Microbiology Data at ICAAC/ICC 2015 Conference 158
Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 159
Aug 20, 2015: Dipexium Pharmaceuticals Surpasses Treatment Of 50% Of Subjects In Pivotal Phase 3 Clinical Trial 160
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 161
Disclaimer 162

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2016 13
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Comparative Analysis by Unknown Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2016 25
Diabetic Foot Ulcers - Pipeline by Adocia, H1 2016 26
Diabetic Foot Ulcers - Pipeline by Bayer AG, H1 2016 27
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 28
Diabetic Foot Ulcers - Pipeline by Celgene Corporation, H1 2016 29
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2016 30
Diabetic Foot Ulcers - Pipeline by Dipexium Pharmaceuticals LLC, H1 2016 31
Diabetic Foot Ulcers - Pipeline by EyeGene, Inc., H1 2016 32
Diabetic Foot Ulcers - Pipeline by FirstString Research, Inc., H1 2016 33
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1 2016 34
Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1 2016 35
Diabetic Foot Ulcers - Pipeline by Innovaxis, H1 2016 36
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corporation, H1 2016 37
Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 38
Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H1 2016 39
Diabetic Foot Ulcers - Pipeline by MediWound Ltd., H1 2016 40
Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 41
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co., Ltd., H1 2016 42
Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics, Inc., H1 2016 43
Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1 2016 44
Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics, Inc., H1 2016 45
Diabetic Foot Ulcers - Pipeline by Sanofi, H1 2016 46
Diabetic Foot Ulcers - Pipeline by Stratatech Corporation, H1 2016 47
Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2016 48
Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H1 2016 49
Diabetic Foot Ulcers - Pipeline by Theravasc, Inc., H1 2016 50
Diabetic Foot Ulcers - Pipeline by Tissue Therapies Limited, H1 2016 51
Diabetic Foot Ulcers - Pipeline by USV Limited, H1 2016 52
Diabetic Foot Ulcers - Pipeline by Vida Therapeutics Inc., H1 2016 53
Diabetic Foot Ulcers - Pipeline by ViroMed Co., Ltd., H1 2016 54
Assessment by Monotherapy Products, H1 2016 55
Number of Products by Stage and Target, H1 2016 57
Number of Products by Stage and Mechanism of Action, H1 2016 59
Number of Products by Stage and Route of Administration, H1 2016 61
Number of Products by Stage and Molecule Type, H1 2016 63
Diabetic Foot Ulcers Therapeutics - Recent Pipeline Updates, H1 2016 126
Diabetic Foot Ulcers - Dormant Projects, H1 2016 150
Diabetic Foot Ulcers - Dormant Projects (Contd..1), H1 2016 151
Diabetic Foot Ulcers - Dormant Projects (Contd..2), H1 2016 152
Diabetic Foot Ulcers - Discontinued Products, H1 2016 153